IBO IBO
Company Profile ↓Company Overview
IBO (IBO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -36.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -36.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -36.00% |
| 1 Year: | -36.00% |
Stock Price Performance
| 1 Year: | -30.53% |
| 6 Months: | -14.85% |
| 3 Months: | -33.13% |
| 1 Month: | -4.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -36.0% CAGR over 5 years.
- Trading 44.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.00K | - | - | - | - | - | - | - | - | 7.00K | 18.00K | 7.00K |
| Operating Income | -750.00K | -889.00K | -803.00K | -1.01M | -1.08M | -771.00K | -626.00K | -1.13M | -1.01M | -1.15M | -948.00K | -2.29M |
| Net Income | -799.00K | -2.24M | -849.00K | -1.12M | -1.18M | -962.00K | -889.00K | 4.25M | -1.27M | -14.35M | -1.47M | -2.29M |
| Diluted EPS | 0.00 | -0.03 | -0.01 | -0.02 | -0.02 | -0.10 | -0.09 | 0.06 | -0.11 | -1.18 | -0.12 | -0.02 |
| R&D Expense | 206.00K | 330.00K | 179.00K | 266.00K | 357.00K | 183.00K | 121.00K | 82.00K | 103.00K | 75.00K | 52.00K | 46.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 50.00K | - | - | 32.00K |
| Operating Income | -3.40M | -4.03M | -28.75M | -4.28M |
| Net Income | -7.25M | -4.34M | -24.71M | -11.84M |
| Diluted EPS | -0.10 | -0.07 | -2.30 | -0.38 |
| R&D Expense | 1.23M | 1.69M | 278.00K | 340.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 46.50M | 44.63M | 20.29M | 17.41M |
| Total Equity | 39.92M | 29.56M | 25.22M | 4.26M | 12.61M |
| Cash & Equivalents | - | 2.00K | 1.00K | 2.00M | 3.00K |
| Total Liabilities | - | 13.83M | 16.37M | 13.05M | 1.85M |
| Current Liabilities | - | 10.59M | 13.14M | 9.79M | 1.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -2.24M | -2.85M | -2.85M | -1.89M |
| Investing Cash Flow | -349.00K | -15.00K | 2.00K | 3.00K |
| Financing Cash Flow | 2.55M | 2.87M | 4.85M | -109.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -6,808.0% | - | - | -13,381.2% |
| Net Margin % | -14,510.0% | - | - | -36,993.8% |
| ROE % | -24.5% | -17.2% | -580.1% | -93.9% |
| ROCE % | -9.5% | -12.8% | -273.7% | -26.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IBO
9 Communication Services Stocks Moving In Tuesday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPMld4UC1LMmFZdzRpUURJdkFnanc4LUoyejZJbGlxV0hpZk1KdGtvME5rNDdjbjh2T0ZfZVNZeU8xTzFnZ0ZPczl1S2RoNmxWU0RNeG9ncW5CQndxMWFQMGFHa0ptemwwQ1VGbllnTmFfaUViX2kwTWR1UlVBWmFoT1h3N3VjT1RpOTRVMm…
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in July 2026 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxORmRaa0RqY0lHbnh4VHpjZEFiUlEzSFFqaUNIbHBfWU1TaUJJSkRVX0N2Rm0wZFJEYXpHaWRVNVRsTEJwR1BDblZrU2t2UTlCUzMzTXlCZUNlT2Z1ek1QczhZUXZBOXR3WFlGaFNSSE9uRGNkNHJNc0ZPZkJYVzBYRjhSXzVzc2FKeUIyNF…
IBO|Impact Biomedical Inc|Price:0.430| - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBhOWhIbzFvMGphVXJ2RHZ3NW5pYTVTTnFEVFloQlJnc0p6eUZEbWJLNndyOWxLeWV2NlpYdGtWcnJ6Z2VURmdMSWt0SVNPNVdmV2RPbDk0VHpVRmhxTEU4cFdVTTJxSkM0d0pZaA?oc=5" target="_blank">IBO|Impact Biomedical…
IBO Stock Spikes Pre-Market: Retail Traders Pile Into Biotech Penny Stock After Merger Update - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSzhVR05aTkpvaU1tVlA5d1F1NVdidENreU1zMlBKZ08yTTdlMVF5N212cXV4MHQzUEJkMU9BdF9Ld3NpTXBVQVVNLVRmWjIySTgzQlJDR1g4RkNnUGxEejRfUjd2djFLQzZXYXp0aEpzSWZsYTl1UER6YU1hMjZaVXVGQlNaejYzMkYyTn…
Impact Biomedical Inc (IBO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE5nWFlIcnJuQ0gwNEpDUVl4dDJreGpzdzhTZDJtbHVBLWd1a2VhcDRKSWZyWUtrQTk2RkJpaUJ6dFh0T0RXU3RQTjBsQnZHeVQ3c2s0YlZ3MWNvdDBiTlRoUk9FZ01tVU5RY1pfSFlPcw?oc=5" target="_blank">Impact Biomedical…
Impact BioMedical (IBO) Slides 8.6% as Stock Nears Critical $0.44 Support Level - New Highs New Lows - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPT2pXQ25kSm1zejIxVXVhM25KYXpvOUZKR3BqSFJCVmhLa1RtS2RLNVNsVVUyRTNSYVZlOERBOU9TZ2xta3FWWUJSTExpa0dMOGVtZ1kzVDNRSUxVQjUyTFdvVVBnRGk1UVR5WThxSnp4VkE3R1ZzbE94VDhYTjJybXAtZFp1QXZkcFBvRk…
IBO — Frequently Asked Questions
What is the current share price of IBO?
As of 2026-08-05 17:25 PDT, IBO trades at $0.43 on NASDAQ/NYSE. Its 52-week range is $0.40 to $0.78.
What is the P/E ratio of IBO?
IBO trades at a trailing price-to-earnings (P/E) ratio of -1.13.
What is the return on equity (ROE) of IBO?
IBO has a return on equity (ROE) of -93.89%. Its return on capital employed (ROCE) is -26.36%.
Is IBO a good stock to buy?
This page provides a data-driven analysis of IBO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.